Mohit Khera, MD
Urology · Houston, TXNPI 1669677381
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 59.0% of the total. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $1115.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$253K
- Endo Pharmaceuticals Inc.$39K
- Antares Pharma, Inc.$35K
- Besins Healthcare Ireland Limited$20K
- Verity Pharmaceuticals Inc.$17K
- Metuchen Pharmaceuticals$16K
- plus $48K from 16 others
Across 16 payments — averaging $6506.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$38K
- Endo Pharmaceuticals Inc.$37K
- Boston Scientific$27K
- Acerus Pharmaceuticals Corporation$2K
- AbbVie$688
What the payments were for
- Consulting fees$169,02939%
- Speaking & faculty fees$199,77647%
- Grants$1,5000%
- Travel & lodging$49,44212%
- Food & beverage$8,3592%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 221 | $252,666 |
| Endo Pharmaceuticals Inc. | 45 | $38,519 |
| Antares Pharma, Inc. | 21 | $34,540 |
| Besins Healthcare Ireland Limited | 5 | $20,176 |
| Verity Pharmaceuticals Inc. | 8 | $17,486 |
| Metuchen Pharmaceuticals | 7 | $16,454 |
| Acerus Pharmaceuticals Corporation | 12 | $12,958 |
| Endo USA, Inc. | 11 | $7,524 |
| Marius Pharmaceuticals, Inc | 2 | $7,000 |
| Coloplast | 25 | $5,828 |
| AbbVie | 7 | $5,650 |
| Clarus Therapeutics Inc. | 6 | $4,490 |
| Tolmar Pharmaceuticals, Inc. | 2 | $2,370 |
| Novo Nordisk | 1 | $1,965 |
| Innovation Technologies Inc | 2 | $179 |
| Laborie Medical Technologies Corp. | 1 | $125 |
| Astellas Pharma US Inc | 2 | $103 |
| Procept Biorobotics Corporation | 2 | $64 |
| Johnson & Johnson | 1 | $29 |
| Ambu Inc. | 1 | $19 |
| Pfizer | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTRA$66,383
- XIAFLEX$44,979
- GENERAL ERECTILE DYSFUNCTION$41,608
- TLANDO$33,559
- GENERAL - THERAPIES$29,870
- XYOSTED$25,822
- AMS$24,302
- Androgel$18,676
- AdVance XP$17,650
- Stendra$16,454
- JATENZO$13,101
- KYZATREX$13,000
- Natesto$12,765
- ADVANCE$11,830
- TITAN$5,298
- GENERAL VASCULAR ACCESS$4,000
- AMS 700 CXR RTE KIT$3,886
- NOCDURNA$3,000
- AMS 700$2,396
- ELIGARD$2,370
How this compares
$428,173 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 107 | $98,984 |
| MounjaroTirzepatide | 34 | $45,973 |
| TestopelTestosterone | 37 | $44,776 |
| MyrbetriqMirabegron | 39 | $31,040 |
| XyostedTestosterone Enanthate | 11 | $11,143 |
| Testosterone | 54 | $10,687 |
| Tamsulosin Hcl | 323 | $6,188 |
| Testosterone Enanthate | 68 | $5,428 |
| Testosterone Cypionate | 73 | $4,829 |
| Estradiol | 24 | $3,667 |
| Silodosin | 29 | $3,028 |
| Potassium Citrate ErPotassium Citrate | 25 | $2,461 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 96 | $2,119 |
| Dutasteride | 34 | $2,098 |
| Oxybutynin Chloride ErOxybutynin Chloride | 44 | $1,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Testopel | $38,519 | $44,77637 claims |
| Astellas Pharma US IncMyrbetriq | $103 | $31,04039 claims |
| Antares Pharma, Inc.Xyosted | $34,540 | $11,14311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
- Steven MaislosHouston$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.